|[June 30, 2014]
Premier Biomedical, Inc. (BIEI) Announces Important Patent Award for a Potential Multi-Billion Dollar Drug for the Treatment of Fibromyalgia and Neuralgia
EL PASO, Texas --(Business Wire)--
Premier Biomedical, Inc. (OTCBB: "BIEI") a biopharmaceutical company
focused on developing and commercializing innovative immune system
manipulation therapies for breast cancer, Alzheimer's disease, multiple
sclerosis (MS), traumatic brain injury (TBI), and others today announced
that the United States Patent Office approved a patent on their
proprietary medication "Feldetrex ™", which is designed to relieve the
symptoms of neuropathic pain and fibromyalgia. The William Beaumont Army
Medical Center Principal Investigator is drafting a protocol to conduct
a double-blind, placebo-controlled comparison of this medication and the
leading FDA-approved regimen for these concerns and will be submitting
it for IRB approval in the near future.
President and CEO, William A. Hartman, stated, "We are very excited that
the United States Patnt Office granted our request for a patent on
Feldetrex ™. We are very confident in our ability to perform well in the
upcoming double-blind clinical study because of the favorable responses
we have received to date from the limited number of patients that have
taken the medication thus far. We are applying for FDA approval
immediately and are also confident that our application will be
approved, since Feldetrex ™ consists only of a skillful and proprietary
combination of FDA-approved ingredients. The market for such a
medication worldwide runs into many billions of dollars. We believe that
our medication will also fare very well versus competition due to its
projected lack of serious side effects. The market should see results
very quickly as the double-blind study is tentatively scheduled to be
concluded later this calendar year."
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as
defined in the Private Securities Litigation Reform Act of 1995).
Premier Biomedical, Inc. cautions that statements, and assumptions made
in this news release constitute forward-looking statements and makes no
guarantee of future performance. Forward-looking statements are based on
estimates and opinions of management at the time statements are made.
These statements may address issues that involve significant risks,
uncertainties, estimates made by management. Actual results could differ
materially from current projections or implied results. Premier
Biomedical, Inc. undertakes no obligation to revise these statements
following the date of this news release.
[ Back To Technology News's Homepage ]